Neovasc Announces First Quarter Financial Results and Provides Corporate Update
Vancouver, British Columbia and Minneapolis, Minnesota–(Newsfile Corp. – May 12, 2022) – Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) (“Neovasc” or the “Company”) today reported financial results for the quarter ended March 31, 2022.
Recent Highlights
- Achieved Q1 revenue of approximately $611,000, an increase of 35% over the same period in 2021, delivering a record first quarter.
- Activated 6 sites, enrolled 21 patients, and, of those, randomized the first 4 patients, in the COSIRA II IDE trial for the Neovasc Reducer™ (“Reducer”).
- Obtained renewed NUB-1 reimbursement status in Germany.
- Announced multiple third-party publications supporting safety, efficacy, and cost savings related to use of the Reducer to treat refractory angina.
- Replaced and extended maturity of the Company’s debt with a new debt note with the same lenders, now maturing in December 2025.
- Completed a common share consolidation on April 29, 2022 expected to bring the Company into compliance with the Nasdaq $1 minimum bid price rule on or around May 13, 2022.
- Announced the Dismissal with Prejudice of the class action litigation, expecting a first brief to the Appeals court from the lead plaintiff’s counsel on May 13, 2022.
“The first quarter of 2022 was another record setting first quarter in revenue, with continued progress towards our value-creation strategies, in particular on reimbursement,” said Fred Colen, Neovasc President and Chief Executive Officer. “We advanced the Reducer as a viable option to treat refractory angina in Europe, through direct outreach to key opinion leaders, securing positive reimbursement momentum, and by announcing independent studies demonstrating the value of the Reducer to patient, physicians, and payers at a time when value-based care is increasing in importance. As for the important US market, we qualified, trained and contracted the first several U.S. clinics, and began enrolling patients in the pivotal COSIRA II trial, which we believe will demonstrate the benefits of the Reducer and help to inform a future PMA submission to the FDA.”
Financial Results for the First Quarter Ended March 31, 2022
For the three months ended March 31, 2022, revenues increased by 35% to approximately $611,000, compared to revenues of approximately $452,000 for the same period in 2021.
The cost of goods sold for the three months ended March 31, 2022 was approximately $136,000 compared to approximately $72,000 for the same period in 2021.
The overall gross margin for the three months ended March 31, 2022 was 78% compared to 84% gross margin for the same period in 2021, as the mix of sales was skewed toward sales through distributors, due to a significant COVID-19 wave in Germany, where the Company sells direct, which restricted Reducer procedures in that country.
Total expenses for the three months ended March 31, 2022 were approximately $7.1 million compared to approximately $10.6 million for the first quarter of 2021, representing a decrease of approximately $3.5 million or 33%, substantially due to an approximately $1.6 million reduction in legal and underwriting fees associated with the February 2021 financing, an approximately $1.3 million reduction in share based compensation expenses and an approximately $1.0 million decrease in employee and other product development expenses as the Company indefinitely paused the Tiara TF transfemoral mitral value replacement program in June 2021.
The operating losses and comprehensive losses for the three months ended March 31, 2022 were approximately $6.6 million and $10.4 million, respectively, or $3.75 basic and diluted loss per share, as compared with approximately $10.2 million operating losses and $2.9 million comprehensive loss, or $1.11 basic and diluted loss per share, for the same period in 2021.
The Company ended the quarter with approximately $44.2 million in cash. The Company spent approximately $5.7 million to fund operations, absorbed $1.4 million onto the balance sheet and paid approximately $0.3 million to Strul Medical Group for accrued interest on the old notes in excess of the new $13 million note.
As of May 10, 2022, subsequent to the effect of the share consolidation, the Company had 2,729,122 Common Shares issued and outstanding.
Conference Call and Webcast Information
Neovasc will be hosting a conference call and audio webcast today at 4:30 pm ET to discuss these results. Interested parties may access the conference call by dialing (877) 407-9208 or (201) 493-6784 (International) and reference Conference ID 13729200. Participants wishing to join the call via webcast should use the link posted on the investor relations section of the Neovasc website at neovasc.com/investors/. A replay of the webcast will be available approximately 30 minutes after the conclusion of the call using the link on the Neovasc website.
About Neovasc
Neovasc is a specialty medical device company that develops, manufactures, and markets products for the rapidly growing cardiovascular marketplace. Its products include Reducer, for the treatment of refractory angina, which is under clinical investigation in the United States and has been commercially available in Europe since 2015, and Tiara™ for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe. For more information, visit: www.neovasc.com.
NEOVASC INC.
Condensed Interim Consolidated Statements of Financial Position
(Expressed in U.S. dollars)
| March 31, 2022 |
December 31, 2021 |
|||||
| ASSETS | ||||||
| Current assets | ||||||
| Cash and cash equivalents | $ | 44,162,789 | $ | 51,537,367 | ||
| Accounts receivable | 1,393,432 | 1,369,455 | ||||
| Finance lease receivable | 17,551 | 43,543 | ||||
| Inventory | 1,402,855 | 1,480,077 | ||||
| Prepaid expenses and other assets | 972,322 | 787,734 | ||||
| Total current assets | 47,948,949 | 55,218,176 | ||||
| Non-current assets | ||||||
| Restricted cash | 480,912 | 469,808 | ||||
| Right-of-use asset | 376,423 | 456,339 | ||||
| Property and equipment | 165,993 | 182,041 | ||||
| Deferred loss on 2020 derivative warrant liabilities | 1,990,709 | 4,300,484 | ||||
| Deferred loss on 2021 derivative warrant liabilities | 9,084,344 | 9,898,475 | ||||
| Total non-current assets | 12,098,381 | 15,307,147 | ||||
| Total assets | $ | 60,047,330 | $ | 70,525,323 | ||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current liabilities | ||||||
| Accounts payable and accrued liabilities | $ | 3,472,350 | $ | 4,629,163 | ||
| Lease liabilities | 250,667 | 273,145 | ||||
| 2019 Convertible notes | – | 38,633 | ||||
| 2020 Convertible notes, warrants and derivative warrant liabilities |
– | 40,587 | ||||
| Total current liabilities | 3,723,017 | 4,981,528 | ||||
| Non-Current Liabilities | ||||||
| Lease liabilities | 207,139 | 272,652 | ||||
| 2019 Convertible notes | – | 6,548,796 | ||||
| 2020 Convertible notes, warrants and derivative warrant liabilities | 452,663 | 6,088,728 | ||||
| 2021 Derivative warrant liabilities | 315,659 | 405,508 | ||||
| 2022 Convertible notes | 11,577,235 | – | ||||
| Total non-current liabilities | 12,552,696 | 13,315,684 | ||||
| Total liabilities | $ | 16,275,713 | $ | 18,297,212 | ||
| Equity | ||||||
| Share capital | $ | 440,827,120 | $ | 439,873,457 | ||
| Contributed surplus | 41,322,143 | 40,355,952 | ||||
| Accumulated other comprehensive loss | (6,229,804) | (7,885,024) | ||||
| Deficit | (432,147,842) | (420,116,274) | ||||
| Total equity | 43,771,617 | 52,228,111 | ||||
| Total liabilities and equity | $ | 60,047,330 | $ | 70,525,323 | ||
NEOVASC INC.
Condensed Interim Consolidated Statements of Loss and Comprehensive Loss
For the three months ended March 31,
(Expressed in U.S. dollars)
| 2022 | 2021 | |||||
| REVENUE | $ | 610,747 | $ | 451,794 | ||
| COST OF GOODS SOLD | (136,292) | (72,393) | ||||
| GROSS PROFIT | 474,455 | 379,401 | ||||
| EXPENSES | ||||||
| Selling expenses | 818,896 | 637,979 | ||||
| General and administrative expenses | 3,003,530 | 5,292,569 | ||||
| Product development and clinical trials expenses | 3,269,550 | 4,621,428 | ||||
| TOTAL EXPENSES | 7,091,976 | 10,551,976 | ||||
| OPERATING LOSS | (6,617,521) | (10,172,575) | ||||
| OTHER INCOME/ (EXPENSE) | ||||||
| Interest and other income | 17,963 | 10,020 | ||||
| Interest and other expense | (349,840) | (40,409) | ||||
| Gain/(Loss) on foreign exchange | 10,717 | (35,295) | ||||
| Unrealized (loss)/gain on warrants, derivative liability warrants | ||||||
| and convertible notes | (151,343) | 12,450,053 | ||||
| Realized loss on exercise or conversion and extinguishment of | ||||||
| warrants, derivative liability warrants and convertible notes | (1,845,822) | (2,114,651) | ||||
| Amortization of deferred loss | (1,223,564) | (2,265,290) | ||||
| TOTAL OTHER INCOME/ (EXPENSE) | (3,541,889) | 8,004,428 | ||||
| LOSS BEFORE TAX | (10,159,410) | (2,168,147) | ||||
| Tax recovery | – | 732 | ||||
| LOSS FOR THE YEAR | $ | (10,159,410) | $ | (2,167,415) | ||
| OTHER COMPREHENSIVE LOSS FOR THE YEAR | ||||||
| Fair market value changes in convertible notes due to changes in own credit risk | (216,938) | (705,586) | ||||
| (216,938) | (705,586) | |||||
| LOSS AND OTHER COMPREHENSIVE LOSS FOR THE YEAR | $ | (10,376,348) | $ | (2,873,001) | ||
| LOSS PER SHARE | ||||||
| Basic and diluted loss per share | $ | (3.75) | $ | (1.11) |
Contacts
Investors
Mike Cavanaugh
ICR Westwicke
Phone: +1.617.877.9641
Email: Mike.Cavanaugh@westwicke.com
Media
Sean Leous
ICR Westwicke
Phone: +1.646.866.4012
Email: Sean.Leous@westwicke.com
Forward0Looking Statement Disclaimer
Certain statements in this news release contain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws that may not be based on historical fact. When used herein, the words expect, anticipate, estimate, may, will, should, intend, believe, and similar expressions, are intended to identify forward-looking statements. Forward-looking statements may involve, but are not limited to, the expectation of the Company’s future compliance with the Nasdaq minimum price rule and the timing thereof, the expected timing of the first brief to the Appeal’s court from the lead plaintiff, the belief that the COSIRA II trial will demonstrate the benefits of the Reducer and help to inform a future PMA submission to the FDA and the growing cardiovascular marketplace. Forward-looking statements are based on estimates and assumptions made by the Company in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that the Company believes are appropriate in the circumstances. Many factors could cause the Company’s actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including those described in the Risk Factors section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2021 and in the Management’s Discussion and Analysis for the three months ended March 31, 2022 (copies of which may be obtained at www.sedar.com or www.sec.gov). These factors should be considered carefully, and readers should not place undue reliance on the Company’s forward-looking statements. The Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/123848
